Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04804566 · ClinicalTrials.gov registry record
Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients
A clinical trial, sponsored by Amicus Therapeutics.
- Completed
- Registry status
- 44
- Enrollment target
NCT04804566: Completed study, sponsored by Amicus Therapeutics.
NCT04804566 is a clinical trial that has completed, run by Amicus Therapeutics. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04804566 has completed, sponsored by Amicus Therapeutics.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
The objective of this study is to increase the understanding surrounding the choices presented to patients and families impacted by Fabry disease.
Primary Outcome
The goal of the statistical analysis is to uncover patterns and trends that provide both evidence and context for the treatment choices and experiences of patients and families impacted by Fabry disease. All findings will be summarized in the final report, which will not identify any respondent as described above. At the conclusion of this study, the researchers may publish their findings in a medical / scientific journal.
Interventions
- OTHER This is a non-interventional study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2023-11-01 |
What the finished NCT04804566 record still lists
NCT04804566 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 44 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which This is a non-interventional study is the first listed.
NCT04804566 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04804566 about?
NCT04804566 is a clinical study titled "Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients". The objective of this study is to increase the understanding surrounding the choices presented to patients and families impacted by Fabry disease.
What is the current status of trial NCT04804566?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2023-03-01. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT04804566?
The interventions under investigation include: This is a non-interventional study (OTHER).
Who is sponsoring clinical trial NCT04804566?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI